Next 10 |
home / stock / pcsa / pcsa articles
Over the past twenty days of trading, Processa Pharmaceuticals Inc. (OTCMKTS: PCSA), from May 13, 2020 to September 23, 2020 there is a potential ...
Shares of Aon plc (NYSE:AON) fell sharply during Friday's session after the company reported worse-than-expected quarterly financial results. ...
Shares of Alphabet Inc. (NASDAQ:GOOGL) (NASDAQ:GOOG) rose sharply in today's pre-market trading the company posted upbeat results for its firs...
U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling by around 250 points on Thursday. The Dow traded down 1.55% to 3...
U.S. stocks traded lower this morning, with the Dow Jones index tumbling by more than 500 points on Thursday. Following the market opening Thursday...
The Dow Jones index closed higher by around 150 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concer...
The Dow Jones index closed higher by more than 350 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or conc...
The Dow Jones index closed lower by more than 300 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or conc...
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite falling over 50 points on Friday The Dow traded up 0.05% to 38,069.66...
News, Short Squeeze, Breakout and More Instantly...
Processa Pharmaceuticals Inc. Company Name:
PCSA Stock Symbol:
OTCMKTS Market:
Processa Pharmaceuticals Inc. Website:
Processa (NASDAQ: PCSA) , a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, today announced positive efficacy results from the preliminary evaluation of its recently completed Phase 1b clinical trial. The...
Eight of 12 evaluable patients (66.7%) had progression-free survival (PFS) ranging from 5 to 11 months At the highest NGC-Cap dose, all three evaluable patients had PFS with two partial responses (PR) and one stable disease (SD) For all NGC-Cap doses, 5-Fluorouracil (5-FU) exp...
Processa Pharmaceuticals (NASDAQ: PCSA) , a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, will be represented at this month’s EF Hutton Annual Global Conference. According to the announcement, ke...